Full-Time

Director – GCP Clinical Quality Assurance

Confirmed live in the last 24 hours

Kymera Therapeutics

Kymera Therapeutics

201-500 employees

Develops targeted protein degradation therapies

Biotechnology
Healthcare

Expert

Belmont, MA, USA

Category
QA & Testing
Quality Assurance
Required Skills
Google Cloud Platform
Requirements
  • Bachelor’s degree in life sciences, nursing, or related field. Advanced degree (MS or MBA) preferred.
  • A minimum of 10+ years of experience in the biopharmaceutical/pharmaceutical industry
  • Working knowledge of relevant FDA, EU, ICH guidelines and regulations
  • Experience with First in Human trial management
  • Extensive knowledge and understanding of ICH E6 GCP Guideline, FDA and EU Requirements
  • Experience and understanding of Data Integrity requirements and electronic systems used in Clinical trials
  • Direct experience in managing Health Authority GCP Inspections. Experience supporting BIMO inspections is highly preferred
  • Proven experience with developing strong partnerships with cross functional key stakeholders to ensure that strategic business goals are met through the sharing of knowledge and teamwork
  • Extensive knowledge and understanding of all related study monitoring activities
  • Comprehensive understanding of the infrastructure and operational characteristics of CROs and centralized services
  • Strong problem solving and critical thinking skills, including an ability to combine attention to detail with a big picture perspective
  • Ability to drive results on time and take ownership and accountability for shared information
  • Strong communication and influencing skills, as well as problem solving ability to evaluate quality matters and make decisions utilizing risk-based approach
  • Experience with authoring and reviewing clinical regulatory filings
  • Ability to travel up to 15%
Responsibilities
  • Providing quality oversight and compliance support to all non-clinical and clinical development programs including the development of strategic clinical quality oversight plans
  • Serve as a member of clinical study teams, providing GLP/GCP/GVP compliance guidance, to achieve continuous quality improvement and effective quality assurance
  • Implement tolerance limits, metrics and key performance indicators to drive quality compliance and continuous improvement
  • Provide day-to-day quality and compliance support, including issue management (triage/investigation/actions) protocol deviation review and trending
  • Assist and advise in the development of CAPA plans in response to Quality Events/audits/inspections and follow-up on CAPAs
  • Assist with developing and executing the R&D Quality strategy while ensuring that it aligns with Kymera’s business strategy, GCP/GLP/GVP standards, and FDA/EMA/ICH requirements
  • Develop, implement and monitor phase appropriate GCP/GLP/GVP Quality programs, policies and procedures to ensure compliance with applicable regulations
  • Develop, implement and execute a risk-based audit strategy for clinical and non-clinical studies
  • Lead and manage GLP/GCP/GVP audits program including oversight of consultant mediated and/or self-conducted Vendor, System, Study, and Process audits
  • Participate in the evaluation and selection of CROs and other GLP/GCP/GVP service providers and establish Quality Agreements, as required
  • Provide training sessions and mentor teams on topics related to GLP/GCP/GVP quality and related global regulations
  • Review key non-clinical, safety and clinical documents including protocols/amendments, reports, study plans and regulatory documents (e.g. DSUR, IB, IND)
  • Maintain an inspection awareness culture leading to a successful Inspection Readiness Program
  • Establish Quality management governance and escalation structure and periodically report the state of R&D Quality and compliance to management

Kymera Therapeutics develops treatments by targeting and breaking down specific proteins that contribute to diseases, particularly cancer and immune disorders. Their main technology, the Pegasus Platform, enables them to identify these harmful proteins and create drug candidates aimed at effectively treating various conditions. Unlike many competitors, Kymera focuses on targeted protein degradation, which can lead to more precise therapies. The company's goal is to create next-generation medicines that address unmet medical needs, supported by partnerships with organizations like Sanofi to enhance their research and development efforts.

Company Stage

IPO

Total Funding

$191.6M

Headquarters

Cambridge, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

16%
Simplify Jobs

Simplify's Take

What believers are saying

  • Kymera's recent $275 million public offering provides substantial capital to advance their clinical programs and expand their pipeline.
  • The FDA Fast Track designation for KT-333 could accelerate its development and bring it to market faster, benefiting patients with relapsed/refractory lymphomas.
  • Positive data from ongoing cancer drug trials and the unveiling of KT-294 highlight Kymera's potential for significant breakthroughs in oncology and immunology.

What critics are saying

  • The high costs and long timelines associated with biopharmaceutical R&D could strain Kymera's financial resources despite recent funding.
  • Dependence on partnerships, such as with Sanofi, introduces risks related to collaboration dynamics and milestone achievements.

What makes Kymera Therapeutics unique

  • Kymera Therapeutics leverages its proprietary Pegasus Platform for targeted protein degradation, setting it apart from traditional drug development approaches.
  • Their strategic partnership with Sanofi underscores their credibility and enhances their research capabilities, unlike smaller biotech firms with limited collaborations.
  • Kymera's focus on developing first-in-class therapies for cancer and immune disorders positions them uniquely in the biopharmaceutical market.

Help us improve and share your feedback! Did you find this helpful?